全文获取类型
收费全文 | 1025512篇 |
免费 | 72057篇 |
国内免费 | 2842篇 |
专业分类
耳鼻咽喉 | 13735篇 |
儿科学 | 32361篇 |
妇产科学 | 28564篇 |
基础医学 | 144182篇 |
口腔科学 | 26953篇 |
临床医学 | 87448篇 |
内科学 | 210256篇 |
皮肤病学 | 20422篇 |
神经病学 | 83707篇 |
特种医学 | 40433篇 |
外国民族医学 | 338篇 |
外科学 | 160195篇 |
综合类 | 20683篇 |
现状与发展 | 1篇 |
一般理论 | 406篇 |
预防医学 | 75274篇 |
眼科学 | 23308篇 |
药学 | 72718篇 |
1篇 | |
中国医学 | 2077篇 |
肿瘤学 | 57349篇 |
出版年
2021年 | 8225篇 |
2019年 | 8807篇 |
2018年 | 11912篇 |
2017年 | 9241篇 |
2016年 | 10089篇 |
2015年 | 11547篇 |
2014年 | 16417篇 |
2013年 | 24926篇 |
2012年 | 34220篇 |
2011年 | 36577篇 |
2010年 | 21788篇 |
2009年 | 20628篇 |
2008年 | 34533篇 |
2007年 | 36576篇 |
2006年 | 36315篇 |
2005年 | 35902篇 |
2004年 | 34341篇 |
2003年 | 32910篇 |
2002年 | 32187篇 |
2001年 | 42568篇 |
2000年 | 43472篇 |
1999年 | 37512篇 |
1998年 | 11530篇 |
1997年 | 10476篇 |
1996年 | 10112篇 |
1995年 | 9454篇 |
1994年 | 8972篇 |
1993年 | 8427篇 |
1992年 | 28923篇 |
1991年 | 27611篇 |
1990年 | 26974篇 |
1989年 | 25889篇 |
1988年 | 24077篇 |
1987年 | 23657篇 |
1986年 | 22685篇 |
1985年 | 21634篇 |
1984年 | 16392篇 |
1983年 | 14016篇 |
1982年 | 8785篇 |
1979年 | 14961篇 |
1978年 | 10556篇 |
1977年 | 8969篇 |
1976年 | 8436篇 |
1975年 | 9223篇 |
1974年 | 10968篇 |
1973年 | 10442篇 |
1972年 | 9861篇 |
1971年 | 9082篇 |
1970年 | 8726篇 |
1969年 | 8151篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
K S McGrew R F Ittenbach R H Bruininks B K Hill 《Research in developmental disabilities》1991,12(2):181-199
Data obtained on a sample of persons with mild to profound degrees of mental retardation (N = 8255) and ranging from birth to 98 years of age were factor analyzed to provide information on the structure of maladaptive behavior relative to age and degree of mental retardation. Using the Problem Behavior scales of the Inventory for Client and Agency Planning, two principal factors emerged for children with mild to profound degrees of retardation: Internalized Maladaptive and Externalized Maladaptive. For adolescents and young adults, a three-factor solution which varied by degree of retardation was most appropriate. For middle and older adults, three- and four-factor solutions were identified across all ages and degrees of retardation. Across all samples as many as six different types of dimensions were identified, indicating that the structure of maladaptive behavior may well be influenced by age and level of mental retardation. 相似文献
992.
The Mauthner cell (M-cell) of the ‘weakly electric fish’ Gymnotus carapo was investigated with electrophysiological techniques. The antidromic action potential, the recurrent inhibitory input and the posterior VIIIth nerve excitatory input in this cell exhibited characteristics similar to those described in the goldfish. In addition, we found an excitatory input evoked by spinal stimulation at intensities subthreshold for M-cell axons. 相似文献
993.
994.
995.
Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis 总被引:4,自引:0,他引:4
J. S. Hwang S. T. Tu T. S. Yang J. F. Chen C. J. Wang K. S. Tsai 《Osteoporosis international》2006,17(3):373-378
This study compared the clinical efficacy, safety, and tolerability of daily subcutaneous injections of teriparatide and salmon
calcitonin in the treatment of postmenopausal women with established osteoporosis in Taiwan. This 6-month, multicenter, randomized,
controlled study enrolled 63 women with established osteoporosis. They were randomized to receive either teriparatide 20 μg
or calcitonin 100 IU daily in an open-label fashion. Lumber spine, femoral neck, total hip bone mineral density (BMD), and
biochemical markers of bone turnover were measured, and adverse events and tolerability were recorded. The results at 6 months
showed that patients using teriparatide had larger mean increases in spinal BMD than those who used calcitonin (4.5% vs. 0.1%),
but the BMD changes in these two groups at the femoral neck and the total hip were not significant. There were also larger
mean increases in bone markers in the teriparatide group than in the calcitonin group (bone specific alkaline phosphatase
142% vs. 37%; osteocalcin 154% vs. 23%). We conclude that teriparatide has more positive effects on bone formation than salmon
calcitonin, as shown by the larger increments of lumbar spine BMD and bone formation markers, and caused only mild adverse
events and no significant change in liver, kidney or hematological parameters. Compared with the published global results,
teriparatide seems to be equally effective and safe to use in this Asian population. 相似文献
996.
F. Madsen 《Clinical and experimental allergy》2006,36(6):850-851
997.
998.
999.
1000.
Najat C Daw Wayne L Furman Clinton F Stewart Lisa C Iacono Mark Krailo Mark L Bernstein Janet E Dancey Rose Anne Speights Susan M Blaney James M Croop Gregory H Reaman Peter C Adamson 《Journal of clinical oncology》2005,23(25):6172-6180
PURPOSE: Epidermal growth factor receptor is expressed in pediatric malignant solid tumors. We conducted a phase I trial of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in children with refractory solid tumors. PATIENTS AND METHODS: Gefitinib (150, 300, 400, or 500 mg/m2) was administered orally to cohorts of three to six patients once daily continuously until disease progression or significant toxicity. Pharmacokinetic studies were performed during course one (day 1 through 28). RESULTS: Of the 25 enrolled patients, 19 (median age, 15 years) were fully evaluable for toxicity and received 54 courses. Dose-limiting toxicity was rash in two patients treated with 500 mg/m2 and elevated ALT and AST in one patient treated with 400 mg/m2. The maximum-tolerated dose was 400 mg/m2/d. The most frequent non-dose-limiting toxicities were grade 1 or 2 dry skin, anemia, diarrhea, nausea, and vomiting. One patient with Ewing's sarcoma had a partial response. Disease stabilized for 8 to > or = 60 weeks in two patients with Wilms' tumor and two with brainstem glioma (one exophytic). At 400 mg/m2, the median peak gefitinib plasma concentration was 2.2 microg/mL (range, 1.2 to 3.6 microg/mL) and occurred at a median of 2.3 hours (range, 2.0 to 8.3 hours) after drug administration. The median apparent clearance and median half-life were 14.8 L/h/m2 (range, 3.8 to 24.8 L/h/m2) and 11.7 hours (range, 5.6 to 22.8 hours), respectively. Gefitinib systemic exposures were comparable with those associated with antitumor activity in adults. CONCLUSION: Oral gefitinib is well tolerated in children. Development of the drug in combination with cytotoxic chemotherapy will be pursued. 相似文献